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Summary
Although plant expression systems used for production of therapeutic proteins have the
advantage of being scalable at a low price, the downstream processing necessary to obtain pure
therapeutic molecules is as expensive as for the traditional Chinese hamster ovary (CHO)
platforms. However, when edible plant tissues (EPTs) are used, there is no need for exhaustive
purification, because they can be delivered orally as partially purified formulations that are safe
for consumption. This economic benefit is especially interesting when high doses of recombinant
proteins are required throughout the treatment/prophylaxis period, as is the case for antibodies
used for oral passive immunization (OPI). The secretory IgA (SIgA) antibodies, which are highly
abundant in the digestive tract and mucosal secretions, and thus the first choice for OPI, have
only been successfully produced in plant expression systems. Here, we cover most of the up-to-
date examples of EPT-produced pharmaceuticals, including two examples of SIgA aimed at oral
delivery. We describe the benefits and drawbacks of delivering partially purified formulations and
discuss a number of practical considerations and criteria to take into account when using plant
expression systems, such as subcellular targeting, protein degradation, glycosylation patterns and
downstream strategies, all crucial for improved yield, high quality and low cost of the final
product.
Introduction
Ever since the production of the first therapeutic protein in plants
more than two decades ago, plant production platforms have
matured and yielded the first commercially available plant-made
pharmaceuticals for both human and veterinary applications
(Grabowski et al., 2014; Sack et al., 2015a; Yoshiola et al.,
2012). Within the wide repertoire of therapeutic proteins,
antibodies are among the most popular, due to their enormous
potential for the treatment of a wide range of diseases such as
certain cancers, autoimmune diseases and infectious diseases.
The number and types of antibodies expressed in plants have
increased incessantly since the first reports in 1989 (Hiatt et al.,
1989), and in recent years, some plant-made antibodies (PMAbs)
have been presented as promising therapeutic solutions. For
instance, the safety and immunogenicity of personalized anti-
bodies to treat patients with non-Hodgkin’s lymphoma, produced
by Large Scale Biology Corporation (McCormick et al., 2008) and
Icon Genetics (http://www.icongenetics.com), have been demon-
strated in phase I clinical trials. CaroRX (Planet Biotechnology
INC, Hayward, CA, USA), an oral topical solution based on
antibodies against Streptococcus mutans to prevent dental caries
(De Muynck et al., 2010; Larrick et al., 2001; Ma, 1988; Wycoff,
2005), was evaluated in phase I and II clinical trials in the United
States and has been registered as a medical device in Europe
(Larrick et al., 1998). The first good manufacturing practice
(GMP)-compliant, plant-derived monoclonal antibody (mAb) to
undergo clinical testing in Europe was the human P2G12 against
HIV-1, which has been shown to be safe and well tolerated in
healthy women when administered intravaginally (Ma et al.,
2015). Finally, ZMapp, a cocktail comprising three individual
mAbs directed against Ebola, was able to reverse Ebola disease in
100% of the infected Rhesus macaques (Qiu et al., 2014). The
recent outbreak of Ebola in West Africa brought attention to this
antibody cocktail, which was delivered to a handful of patients
with their signed consent. In February 2015, ZMapp received
approval from the FDA as an investigational new drug, allowing
the start of clinical trials in Liberia.
Although mammalian cells (Wurm, 2004) or baculovirus-
infected insect cells (Berger et al., 2004) are currently the most
used antibody production systems for the majority of applica-
tions, the use of transgenic plants for the expression of
recombinant antibodies is gaining momentum. Accordingly,
several groups compared the potential of PMAbs as antimicrobial
agents with their commercial ‘biosimilars’. Zeitlin et al. (1998)
compared a humanized antiherpes simplex virus 2 (HSV-2) mAb
expressed in mammalian cell cultures with its counterpart
expressed in soybean, proving not only the similarity in their
stability in mucosal secretions of the human reproductive tract,
but also in the efficacy for the prevention of vaginal HSV-2
infection in mouse. Ko et al. (2003) produced an anti-rabies virus
immunoglobulin G (IgG) in tobacco plants and demonstrated its
effectiveness in vivo, showing a virus-neutralizing activity com-
parable with that of its commercial counterpart. The neutraliza-
tion capacity of the PMAb-based vaginal microbicide against HIV
transmission also proved to be equal or even superior to that of its
counterpart produced in CHO cells (Ramessar et al., 2008).
Moreover, competitive yields have been reported not only at a
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laboratory scale (Giritch et al., 2006; Petruccelli et al., 2006), but
also in prototype industrial set-ups (Bendandi et al., 2010; Vezina
et al., 2009). Upscaling of PMAbs can in theory be achieved more
easily and economically than with the existing animal and insect
cell systems, where it requires expensive investments. Although
no PMAbs are in commercial production yet and costs are difficult
to estimate, it has been calculated by Planet Biotechnology that
the costs of an IgA produced in plants are only 5% compared
with those in mammalian cells (Daniell et al., 2001; Frenzel et al.,
2013). However, the optimization of purification protocols and
strict regulations on growth of transgenic plants in the field
(Directive 2001/18/EC) hamper faster development.
Traits like low-cost upscaling and ease of storage are especially
promising when bulk amounts of antibodies are required, as is
the case, for example for passive immunization (PI), where
repeated high doses have to be applied. The protective effect of
PI is appropriate for rapid responses to emergencies, such as
epidemic outbreaks, protection of newborns against vertical
transmission of viruses from the mother, protection of immuno-
compromised patients and biological warfare threats. Cus-
tomized antibodies can be applied parenterally, intravenously or
even better directly to the mucosae, because most infections are
caused by pathogens that have a mucosal portal of entry.
Antibody application via the oral route to the gastrointestinal
mucosa is called oral passive immunization (OPI).
Edible plant tissues as a platform for production
of mucosal therapeutics
OPI is one of themost promising applications of PMAbs, particularly
when considering that plant species with tissues that are generally
recognized as safe (GRAS) may have lower purification require-
ments. Edible plant tissues (EPTs) could even be consumed safely,
making them ideal platforms for the production of gastrointestinal
therapeutics aimed at oral delivery. Although there are still very few
examples of antibodies produced in EPTs, some edible mucosal
therapeutics have been investigated and set a precedent.
The concept of edible plant-made pharmaceuticals was first
conceived in the early 1990s, when Charles J. Arntzen championed
the idea ofmaking vaccines in edible fruits.While visiting Bangkok,
he saw amother soothe a crying baby by offering pieces of banana,
inspiring him with the idea to produce vaccines in genetically
engineered food. The advantages would be enormous: yearly and
local growth of plants would not only significantly reduce costs and
avoid the need for refrigerated transportation over long distances,
but vaccines in EPTswould also not requiremedical personnel or the
use of syringes, which, apart from their additional cost, can be
contaminated and lead to infections (Mason et al., 1996). Unfor-
tunately, several limitations to the concept appeared; among
others, the possible development of immunotolerance to target
peptides or proteins, which has to be addressed on a case-by-case
basis, the difficulty to control dosage requirements and the
fluctuating dosage consistency, varying from fruit to fruit, plant
to plant and generation to generation. To deal with the two last
problems, the idea of directly consuming the fruit was abandoned
and substituted by the use of dried or partially purified formula-
tions, for which the dosage could be standardized, while sustaining
low production costs (Tokuhara et al., 2013). Particularly, con-
trolled doses can be achieved using lyophilized plant cells as
formulation. As an example, the plant biotech company Protalix
Biotherapeutics produces lyphilized carrot cells expressing either
anti-TNF antibodies or Glucocerebrosidase aimed for oral delivery
(http://www.protalix.com/development-pipeline/overview-devel-
opment-pipeline.asp). Other noteworthy examples of lyophilized
plant cells expressing biotherapeutics for oral applications are
reviewed in Chan and Daniell (2015).
Since then, a number of vaccines, antibodies and other
mucosal pharmaceuticals have been produced in EPTs for oral
treatments (Table 1). One of the first was a vaccine candidate
based on the heat-labile enterotoxin B (LTB) subunit of entero-
toxigenic Escherichia coli (ETEC) produced in transgenic potato,
which protected against an ETEC challenge in animal studies and
was also immunogenic in humans during a phase I clinical trial
(Haq et al., 1995; Mason et al., 1998; Tacket et al., 1998); the
same was shown when it was produced in transgenic corn
(Tacket, 2007; Tacket et al., 2004). Many examples for Alzhei-
mer’s disease, allergic diseases, or autoimmune and infectious
diseases show that rice is one of the preferred EPTs for
therapeutic protein production (Azegami et al., 2015; Takaiwa
et al., 2015). A first example is the MucoRice-CTB, an oral vaccine
against cholera, which consists of the antigen of the cholera toxin
B (CTB) accumulating in rice seed storage organelles. This vaccine
was shown to induce both mucosal and systemic immunity in
primates (Nochi et al., 2009), and also exhibited cross-reactivity
with the LTB of ETEC in piglets challenged with ETEC, when the
vaccine was orally applied to the nursing sows (Takeyama et al.,
2015). Another rice example for mucosal applications is the
MucoRice-ARP1, containing the variable domain of a rotavirus-
specific llama heavy-chain antibody fragment, which provided
efficient protection against rotavirus disease (Tokuhara et al.,
2013). Also, the group of Takeshi Matsumura in Japan focused
their interest on expressing canine interferon a in strawberries. In
animal trials, they showed that canine interferon-a that was
delivered to beagles by adding dried transgenic strawberries to
the dog feed had a protective and therapeutic effect against the
canine periodontal disease, even at a very low dose (Yoshiola
et al., 2012). Currently, research has advanced to the clinical trial
phase (https://unit.aist.go.jp/bpri/bpri-pmt/member_e.html).
Several therapeutic proteins expressed in the chloroplasts of
lettuce leaves also illustrate the efficiency and low cost of the
production of pharmaceuticals in EPTs, even at industrial set-ups
(Kwon and Daniell, 2015). Su et al. (2015a) produced acid-a
glucosidase (AAG) in lettuce leaves and showed that their natural
encapsulation in the chloroplast was able to avoid the adverse
immune reaction occurring during the protein replacement
therapy for Pompe disease when assayed in mice. Following the
same rationale, Su et al. (2015b) also expressed the coagulation
factor IX (FIX), showing the absence of pathogenic antibodies
after haemophilia treatment in mice. Moreover, Shil et al. (2014)
showed that feeding of mice with bioencapsulated ACE2/Ang-(1–
7) significantly reduced endotoxin-induced uveitis (EIU).
As mentioned above, Protalix Biotherapeutics is engaged in the
development of two new drugs naturally encapsulated within
carrot cells, intended for oral delivery. One of them is the
glucocerebrosidase (GCD) enzyme PRX-112 for the treatment of
Gaucher disease. Feeding experiments with rat and pig as model
animals have shown that active recombinant GCD reached both
liver and spleen, the target organs in the Gaucher disease
(Shaaltiel et al., 2015). Moreover, the recombinant GCD was
found to be safe and well tolerated in all 12 patients in a phase I
clinical trial in Israel. The phase II clinical trial is ongoing for this
product. The other carrot cell-based protein is the anti-tumour
necrosis factor PRX-106 for orally administered, anti-inflamma-
tory treatment. In preclinical studies, PRX-106 alleviated immune-
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mediated hepatitis and reduced interferon-c levels in a mouse
model; in a phase I clinical trial, PRX-106 has been shown to be
safe and well tolerated, to have biological activity in the gut and
to induce regulatory T cells.
There are some examples of antibodies produced in EPTs
intended for PI at the gastrointestinal tract, two of them developed
in our groups. The first one, intended for veterinary use, is the
designer IgAs expressed in Arabidopsis thaliana seeds, consisting
of a fusion between the anti-ETEC llama heavy-chain-only
antibodies and the Fc part of the porcine IgA. These antibodies
have shown to efficiently protect ETEC-challenged piglets against
postweaning diarrhoea when administered in the form of crushed
seeds mixed with the feed (Virdi et al., 2013). The second example
consists of IgA antibodies against rotavirus produced in tomato
fruits. In this work, minimally processed fruit-derived products
(tomato-clarified extract and powder) suitable for oral intake
showed anti-VP8* binding activity and strongly inhibited virus
infection in in vitro virus neutralization assays (Juarez et al., 2012).
Secretory IgA as a target molecule for oral
passive immunotherapy
Although IgA constitutes only 10–15% of the total immunoglob-
ulin in the blood serum, it is the predominant immunoglobulin
class in external secretions such as breast milk, saliva, tears and
the mucosal surfaces of the bronchial, genitourinary and digestive
tracts. The daily human production of 5–15 g of SIgA into
mucous secretions is greater than that of any other immunoglob-
ulin class (Goldsby et al., 2003). SIgA serves as the first line of
defence at mucosal surfaces by neutralizing pathogenic microor-
ganisms. Because of its polymeric form, SIgA can cross-link large
antigens with multiple epitopes. Binding of SIgA to bacterial and
viral surface antigens prevents attachment of the pathogens to
mucosal cells, thus inhibiting viral infection and bacterial colo-
nization. Complexes of SIgAs and antigens are easily entrapped in
the mucus and then eliminated by the ciliated epithelial cells of
the respiratory and genitourinary tract or by peristalsis of the gut.
For this reason, SIgA is the antibody isotope best suited for OPI
(Corthesy, 2003, 2010, 2013).
In spite of all obvious advantages that SIgA presents as a
therapeutic molecule, its recombinant production has rarely been
attempted for commercial purposes, probably due to the tech-
nical difficulties associated with the expression, assembly and
recovery of a protein complex composed of four different
polypeptides [heavy chain (HC), light chain (LC), joining chain
and secretory component (SC)] and comprising a total of 10
individual monomers. Under physiological conditions, the biosyn-
thesis of a SIgA complex requires the cooperation between
plasma cells, which produce dimeric IgAs (dIgAs), and mucosal
epithelial cells that bind the dIgAs via the polymeric immunoglob-
ulin receptor (pIgR). During transcytosis, the pIgR is cleaved,
resulting in the secretion of the SIgA with the IgA-bound pIgR
piece, called SC, wrapped around the IgA. Although some
attempts to produce a correctly assembled SIgA by co-expressing
all four different genes in a single mammalian cell type have been
successful (Chintalacharuvu and Morrison, 1997), the yields need
to be improved and the technology is yet to be developed to
achieve a commercially viable product (Renukuntla et al., 2013).
The first attempt to produce a plant-made SIgA for PI was the
murine hybrid Guy’s 13 (Ma et al., 1995). This technology was
later acquired by Planet Biotechnology (Larrick et al., 2001),
evaluated in phase I and II clinical trials and registered as the
medical device called CaroRX (Weintraub et al., 2005). Since
then, just a few research groups have reported the expression of
SIgA in heterologous systems. Wieland et al. (2005) successfully
expressed chicken SIgAs against Eimeria acervulina in Nicotiana
Table 1 Most relevant antibodies and therapeutic proteins produced in EPTs
Product Target pathogen/disease Plant species/EPT Clinical status Expression level Reference
Capsid protein Norwalk virus Potato Unknown 10–20 lg g1 TW
0.23% TSP
Mason et al. (1996)
Heat-labile
enterotoxin B (LTB)
E. coli Potato, corn Phase I NF Haq et al. (1995)
12.88 lg g1 TW
1.85 lg mg1 lg g1 TP
Mason et al. (1998)
3.7–15.7 lg g1 Tacket et al. (1998)
0.15 mg g1 Tacket et al. (2004)
12.88 lg g1 TW
1.85 lg mg1 lg g1 TP
Tacket (2007)
Virus-like particle (VLP) Hepatitis B, Norwalk virus Potato Unknown 542 ng mg1 TSP Huang et al. (2005)
MucoRice-CTB
(Cholera toxin B subunit)
Cholera Rice Animal trials 30 lg seed1 Nochi et al. (2007)
Takeyama et al. (2015)
MucoRice-ARP1 (Antibody) Rotavirus Rice Unknown 170 lg seed1 Tokuhara et al. (2013)
Canine interferon Gingivitis Strawberries Unknown NF https://unit.aist.go.jp/bpri/bpri-
pmt/member_e.html
VEN100 human lactoferrin Antibiotic-associated diarrhoea Rice Phase II >5 mg g1 Bethell and Huang (2004)
Broz et al. (2013)
PRX-112
glucocerebrosidase (GCD)
Gaucher disease Carrot cells Phase II 3 mg kg1 www.protalix.com
Shaaltiel et al. (2015)
PRX-106 antibody Tumour necrosis factor Carrot cells Phase I NF www.protalix.com
Designer antibodies Enterotoxigenic E. coli A. thaliana seeds Animal trials 0.2% TSW Virdi et al. (2013)
Antibody Rotavirus Tomato N/A 41 lg g1 FW
3.6% TSP
Juarez et al. (2012)
TW is tuber weight, NF is not found, TSP is total soluble protein, TP is total protein, TSW is total seed weight, FW is fresh weight and N/A is not applicable.
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benthaminana leaves. More recently, Virdi et al. (2013) produced
SIgA-like antibodies against ETEC in A. thaliana seeds. Recently,
we also demonstrated the relevance of the proper optimization of
SIgA production in a case-by-case basis, by performing a
combinatorial assembly and analysis of 16 versions of SIgA
against rotavirus transiently expressed in N. benthamiana (Juarez
et al., 2013; Sarrion-Perdigones et al., 2011a). Paul et al. (2014)
expressed and characterized a human SIgA format of the anti-HIV
monoclonal antibody 2G12 using both transgenic tobacco plants
and transient expression in N. benthamiana as expression hosts.
Because the production of human SIgA antibodies at a
commercially viable scale in animal cells remains an unsolved
technological problem, plant-based platforms, and especially
those using EPTs when SIgA production is intended for OPI,
appear to be the most promising candidates.
Practical considerations
As for every therapeutic which is envisioned to be produced in
plants, the design of a plant biofactory for antibody production
requires multiple considerations involving not only the expression
levels of the antibody, but also additional aspects, such as bio-
availability, transformation strategy (Obembe et al., 2011), sub-
cellular targeting, protein degradation, glycosylation patterns and
downstream strategies, all of them influencing the yield, quality
and cost of the final product (Sarrion-Perdigones et al., 2011b).
To date, most of these aspects have been addressed separately,
mainly on an empirical basis. Thus, future optimizations will
probably require designs that integrate all of them following a
global approach.
One of the main challenges of oral delivery of molecules
intended to reach the blood stream is their efficient absorption.
Upon oral administration, the gut epithelium acts as a physical
and biochemical barrier for absorption of proteins, resulting in
low bioavailability. Although this remains an unsolved problem,
certain approaches, such as chemical modification, use of
absorption and penetration enhancers, use of muco-adhesive
polymers and covalent conjugation to carrier molecules such as
the (nontoxic) CTB enabling recognition of a target receptor, can
enhance the oral bioavailability of peptides. However, these
approaches, together with the understanding of the tertiary
structures of macromolecules, need to be evaluated on a case-
by-case basis to efficiently improve the bioavailability of each
target protein (Kwon and Daniell, 2015; Renukuntla et al.,
2013).
Another important challenge is achieving high expression
levels, however, until now a feasible solution resolving this
requirement has not been found. Although the transient expres-
sion system in Nicotiana benthamiana is the fastest strategy for
recombinant protein production, the yields achieved are not
sufficient for obtaining the large quantities of antibodies required
for PI strategies. Moreover, it is not the most adequate system for
production of therapeutic proteins for oral intake of partially
purified formulations, because tobacco leaves lack the GRAS
status. On the contrary, when using the seeds of stably
transformed plants as a production platform, higher yields can
be obtained due to their high protein content-nature and low
water content (Table 1). If even higher amounts are required,
these can be achieved by incorporating a process of lyophilization
of different plant tissues. By removing the water content, the
concentration of the target protein can be increased more than
20-fold (Chan and Daniell, 2015).
Although extracellular secretion is the natural route for
antibodies in mammals, targeting antibody chains to specific
compartments in the plant cell can result in advantages in terms
of stability, yield or downstream processing (Arcalis et al., 2013;
De Muynck et al., 2010). Among the different compartments
that have been tested as destination for recombinant antibodies
(chloroplast, protein storage vacuole, etc.), the secretory pathway
seems to be the most convenient route for correct antibody
folding and assembly, due to the oxidizing environment required
for formation of disulphide bonds, the low abundance of
proteases and the presence of molecular chaperones found in
the ER (Ma et al., 2003). Antibody chains are targeted to the
plant secretory pathway using an appropriate N-terminal signal
peptide, which is either a plant signal peptide (De Buck et al.,
2012), or the native signal peptide of the Ig (Hiatt et al., 1989;
Sainsbury et al., 2008), which works as efficiently in many cases
(De Buck et al., 2012; Hiatt et al., 1989; Sainsbury et al., 2008).
Once in the cis-Golgi, antibodies can either be efficiently retrieved
back to the ER using a C-terminal H/KDEL retention signal, or
secreted into the apoplast, downstream of the secretory pathway
(De Muynck et al., 2009; Petruccelli et al., 2006). Although
several antibodies have been reported to accumulate well in the
apoplast (De Muynck et al., 2009; De Wilde et al., 1998; D€uring
et al., 1990), retention in the ER is often preferred for yield
improvement and for dodging plant-specific, Golgi-derived N-
glycosylation with b-1,2-xylose and core a-1,3-fucose that could
cause immunogenicity in target organisms (Bencurova et al.,
2004; Gomord et al., 2010). However, as reported by De Meyer
et al. (2015) and De Meyer and Depicker (2014), the final protein
destination of H/KDEL-tagged recombinant proteins is unpre-
dictable and, hence, plant-specific N-glycans cannot be effectively
avoided following this strategy. On another front, the progress in
plant glycoengineering has made possible to produce antibodies
with customized and highly homogenous glycosylation patterns,
which can lead to higher product quality and clinical efficacy
(Bosch et al., 2013; Castilho and Steinkellner, 2012; Castilho
et al., 2012; Steinkellner and Castilho, 2015). Different strategies
have been followed to express recombinant proteins with a
mammalian-like N-glycosylation pattern, such as the down-
regulation of endogenous a-1,3-fucosyltransferase (FT) and
b-1,2-xylosyltransferase (XT), the expression of a chimeric form
of the human b1,4-galactosyltransferase (GalT) targeted to a late
Golgi compartment (Bakker et al., 2001; Strasser et al., 2009)
and the addition of terminal sialic residues, by engineering of the
full mammalian N-acetylneuraminic acid (Neu5Ac) biosynthesis
pathway (Castilho et al., 2008, 2010; Loos and Steinkellner,
2014). When glycan adaptation strategies were used for produc-
tion of antibodies, the resulting glycoforms were highly homo-
geneous and showed a dramatic increase in the antibody-
dependent cellular cytotoxicity (ADCC) activity (Whaley et al.,
2011) which points out the benefits of plant-to-human modifi-
cation of the glycan structure.
Recently, a novel and different approach emerged to efficiently
get rid of plant-specific glycosylation. GlycoDelete, a strategy
previously developed for its use in mammalian cells (Meuris et al.,
2014), consists on expressing a plant Golgi-targeted version of
the endo-N-acetyl-b-D-glucosaminidase (endoT) from the fungus
Hypocrea jecorina in mutant plants lacking N-acetylglucosaminyl-
transferase-I (GnTI) activity. These mutants only accumulate high-
mannose glycans which are substrates for the endoT enzyme.
Consequently, the endoT releases the glycan structure from the
target protein, leaving the innermost GlcNAc (which is often
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important to maintain the overall protein fold) attached to the
amino acid backbone (Piron et al., 2015).
Even if it is advisable to mimic mammal glycosylation in injected
therapeutic proteins to avoid unwanted antigenicity, when the
therapeutic proteins are aimed at oral treatment, antigenicity
against the sugars is probably not so determining. Because we
daily consume plant-specific glycans in our diet, plant glycans
attached to these recombinant proteins are not expected to
generate unexpected allergic reactions. Moreover, the concern of
regulatory agencies about glycosylation patterns has probably
decreased significantly after the commercialization of ELELYSO
(Protalix Biotherapeutics, Carmiel, Israel), the injectable GCD from
Protalix Biotherapeutics, produced in carrot cell suspensions,
which showed good results in clinical trials in spite of carrying
plant-specific xylose and fucose residues (Aviezer et al., 2009;
Cox, 2010; Shaaltiel et al., 2007).
As stated above, specific glycosylation patterns can also
improve the stability of antibodies. Plants are heterologous
environments for antibodies, and proteases may affect the
integrity of these during both protein accumulation and protein
extraction. Antibodies may undergo complete hydrolysis, directly
reducing the final yield, or partial degradation, which can alter
the integrity and activity of the final product (Benchabane et al.,
2008; Faye et al., 2005; Hehle et al., 2015). Together with
obtaining a proper glycosylation pattern of the target antibody,
other strategies have been reported to increase both the yield and
quality (nondegraded) of PMAbs. For instance, it has been
proposed that a balanced co-expression of heavy and light chains
is another clue factor for achieving high yields, because
unassembled antibody chains, which are retained by the ER-
resident chaperone BiP, could be degraded via plant ER-
associated degradation systems (Liu and Li, 2014). For this,
stronger promoters should be used to boost the expression of
antibody chains that are limiting the generation of complete
antibody complexes. Other approaches are the use of tissue-
specific promoters to confine transgene expression to compart-
ments with reduced metabolic activity or targeting proteins to
specific cellular organelles. Gene knockout or silencing of plant
peptidases is also a tool to take into account if there is a single or
only a few target peptidases, which are not essential for plant
growth (De Muynck et al., 2010). For the latter, the specific
proteases that are active in the targeted time/space must be
detected. Activity-based probes are being developed, which react
with the active sites of different enzymes – proteases in this case –
in an activity-dependent manner. Proteases can then be identified
and further knocked out if required (Ilyas et al., 2015; Lu et al.,
2015). Finally, the co-expression of recombinant protease
inhibitors interfering with endogenous proteases has also been
proposed (Benchabane et al., 2008; Robert et al., 2013). Apart
from the in planta stability, there is also a high concern regarding
antibody stability in the harsh conditions of the gastrointestinal
tract when these antibodies are aimed for oral delivery. In this
framework, the glycosylation of the antibodies, and more
concretely in the hinge region, also plays a key role (Kim et al.,
1994; Plomp et al., 2015). Another advantage of PMAbs that falls
within this context is that in partially purified formulations for oral
delivery, antibodies are protected by the plant tissue matrix. The
plant cell wall provides a natural barrier to the harsh conditions of
the gastrointestinal gut that can be further improved by targeting
the antibodies to different cell compartments (Sack et al., 2015a).
This benefit is also applicable for proteins produced in plant cell
suspensions, as it is the case for the above-mentioned therapeutic
proteins from Protalix Biotherapeutics, which are naturally
encapsulated within the carrot cells.
Of course, the use of minimally processed formulations relies
on the logical expectation that the edible status of the transgenic
plant tissue remains unaltered. However, it has been repeatedly
argued that transgenesis leads to unintended effects in the final
composition of the plant tissues, such as changes based on the
integration of the transgene, biological interactions caused by
transgene-encoded proteins or spurious somaclonal mutations
(Araki and Ishii, 2015; Heinemann et al., 2011; Schnell et al.,
2015). Although unintended effects have become one of the
most controversial questions about biological safety of genetically
modified organisms (GMOs), risk analysis studies and detailed
GMO characterizations performed until now have not revealed
any harmful unintended effect (Garcıa-Ca~nas et al., 2011; Ladics
et al., 2015). There are several recent publications that assess the
edibility of genetically engineered EPTs producing proteins aimed
for pharmaceutical use, one of them being of our group (Juarez
et al., 2014). In this work, as a way to evaluate the changes in the
tomato composition introduced by IgA production, the proteomic
and metabolomic profiles of transgenic tomatoes expressing
human IgA were analysed and compared with those of non-
transgenic fruits. Although this work itself cannot rule out the
possibility of harmful unintended effects associated with every
single strategy involving IgA production in fruits, the data suggest
that the formulations derived from these IgA tomatoes are as safe
for consumption as equivalent formulations derived from wild-
type tomatoes. A second work, performed by Kurokawa et al.
(2013), describes that no known rice allergens appear to be up-
regulated by genetic modification of MucoRice-CTB, suggesting
that MucoRice-CTB has the potential as a safe oral cholera
vaccine. These two studies are the first step for confirming the
safety of transgenic plants – or their edible tissues – producing
recombinant proteins for mucosal applications. When analysing
the unintended effects produced in GMOs, it is also useful to take
into account a whole-genome and transcriptomic analysis. In this
framework, Kawakatsu et al. (2013) conducted an analysis where
the genome of a rice line expressing a seed-based edible vaccine
containing two pollen allergens was compared with the genome
of its host line. In this study, the authors found that the
differences between both genomes were minor in comparison
with those found when comparing the parental line with other
related rice cultivars, pointing out that most of the alterations
corresponded to somaclonal variation. Moreover, when perform-
ing strand-specific mRNA-Seq, similar transcriptomes were
revealed for both transgenic and parental lines, supporting
genomic integrity between them.
Another important consideration is how to handle minimally
processed plant preparations or partially purified drug substances
to control the quality (e.g. batch-to-batch consistency) of the
recombinant pharmaceutical products according to GMP compli-
ance. The procedures for the GMP/GACP-compliant upstream
production of 2G12 in transgenic tobacco plants have been
recently summarized by Sack et al. (2015b). In general, the
manufacturing of recombinant biologically active substances in
plants is covered at the EU level by the guideline EMEA/CHMP/
BWP/48316/2006 (http://www.ema.europa.eu/docs/en_GB/doc-
ument_library/Scientific_guideline/2009/09/WC500003154.pdf),
which basically adapts aspects of the quality guidance already in
place for other production systems to the special case of
transgenic plants. Although this guideline covers several technical
aspects, such as generation of transformants, banking systems,
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upstream and downstream processing, characterization of active
ingredients and control of contamination with adventitious
agents, it does not specifically address minimally or partially
processed products. It states, however, that process-related
impurities (e.g. host cell proteins, host cell DNA, reagents,
downstream impurities) are expected to differ qualitatively
among different manufacturing processes, and therefore, the
qualitative comparison of these parameters may not be relevant
in bio-similar comparability exercises.
In the absence of specific guidelines covering recombinant
biologics in minimally processed plant tissues, it can be useful to
review and compare the existing guidelines for related products
with similar characteristics, such as herbal medicinal preparations
containing identified active ingredients (e.g. powdered herbal
substances, extracts, essential oils, expressed juices and processed
exudates among others). For those products, active ingredients
are defined as those chemically defined substances or groups of
substances which are generally accepted to contribute substan-
tially to the therapeutic activity, a description that could be easily
assimilated to recombinant biologics made in plants. To ensure
appropriate and consistent quality of medicinal plant/herbal
substances, the Guideline EMEA/HMPC/246816/2005 (http://
www.ema.europa.eu/docs/en_GB/document_library/Scien-
tific_guideline/2011/09/WC500113210.pdf) establishes good
agricultural and collection practices (GACP) for herbal starting
materials. Furthermore, the GMP concept for the manufacture,
processing, packaging and storage of active pharmaceutical
ingredients also applies to medicinal plants/herbal substances as
covered by EU-GMP Guideline Part II (http://www.ecv.de/le-
seproben/781807.pdf). Moreover, in the case of herbal prepara-
tions with constituents of known therapeutic activity, and besides
GACP and GMP considerations, quality assays for marketing
authorization include tests of microbial limits, pesticides and
micotoxins, and specifically require identification of functional
components with validated, specific, stability-indicating assays,
along with details of the used analytical procedure(s) (http://
www.ema.europa.eu/docs/en_GB/document_library/Scien-
tific_guideline/2011/09/WC500113209.pdf). Eventually, similar
specific assays (e.g. ELISA tests, virus neutralization assays) should
be adapted and implemented for recombinant products to ensure
batch-to-batch consistency and stability of active ingredients, that
is recombinant antibodies or biologics. Finally, as an additional
consideration regarding authorization strategies, it should be
noted that herbal preparations with active ingredients for topical
application (e.g. semi-solid formulations) are frequently certified
as medical devices and not as topical drugs. Medical devices are
those that primarily unfold their therapeutic effect by physical
means and do not achieve their principal intended action in or on
the human body by pharmacological, immunological or metabolic
means, but which may be assisted by such means. As mentioned
above, CaroRX received marketing approval in the EU as a
medical device, and similar authorization strategies could be
probably explored for other semi-purified mucosal passive agents
against, for example, skin or oral diseases, as they provide a less
complex marketing authorization process compared with topical
and oral drugs (Korting and Schollmann, 2012).
Final remarks
Plants are emerging systems for the production of recombinant
antibodies. Despite all advantages that plants can offer as
antibody expression systems, so far, very few antibodies have
been subjected to clinical trials (Sack et al., 2015a). There are two
main reasons why PMAbs tend to get trapped in the interface
between animal trials and commercialization. First, because
mammalian systems are already established and have the
dominant share of the market, they somehow obstruct the
natural development of new expression systems, even if these
have striking advantages. Second, the regulatory framework for
the field cultivation of genetically modified plants is highly
demanding, particularly in Europe, as described in the directive
2001/18/EC and its amendment 2008/27/EC.
In all probability, plant antibody expression systems are not
going to replace the mammalian ones. These systems have well-
established production protocols for many antibodies, which have
already gone through the current GMP production and drug
regulations. Production of ‘biosimilars’ in plants will most likely
have to go through strong competition to reach the market.
Therefore, the market of PMAbs will probably have more
opportunities with the production of ‘biobetters’ (therapeutics
with enhanced features and/or efficacy) and of complex
molecules that cannot be produced in mammalian platforms,
such as SIgA or IgM, which can be exploited for mucosal
therapies. Plant platforms present benefits as being human
pathogen free, ensuring rapid availability when using transient
expression systems, providing a la carte glycosylation patterns and
having low production and processing costs. Moreover, if EPTs
are used, the final cost of manufacturing can be dramatically
reduced, because exhaustive purification would no longer be
needed for certain applications. Edible plant tissues with GRAS
status (such as fruits, seeds and certain leaves) can therefore be
utilized as reservoirs of antibodies such as SIgAs for easy long-
time storage and enabling quick availability after minimal
processing when required for OPI. In the case of seeds, due to
their low water content, they can be stored for years without
losing antibody efficacy (Azegami et al., 2015; Virdi et al., 2013).
If using more watery tissues, such as fleshy fruits and leaves, a
step of lyophilization or spray-drying should be included prior to
storing (Juarez et al., 2012; Su et al., 2015b). When using
partially purified products derived from EPTs, it is important to
take into account that an edibility and allergenicity assessment
should be performed to ensure that the plant-derived products
are convenient for oral use.
Overall, plant expression systems are evolving and finding their
niche to be complementary to other established expression
systems. In this framework, EPTs – either seeds or dried tissues –
that offer the possibility of long-lasting, refrigeration-free storage
and low cost of production and downstream processing, will also
be a convenient option for developing countries that cannot afford
costly therapies and/or prophylaxis for certain infectious diseases.
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